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ABSTRACT 
 
Defects in AU-rich elements (ARE)-mediated post-transcriptional control can lead to several 
abnormal processes that underlie carcinogenesis. Here, we performed a systematic analysis of 
ARE-mRNA expression across multiple cancer types. First, the ARE database (ARED) was 
intersected with TCGA databases and others. A large set of ARE-mRNAs was over-represented 
in cancer and, unlike non-ARE-mRNAs, correlated with the reversed balance in the expression 
of the RNA-binding proteins: tristetraprolin (TTP, ZFP36) and HuR (ELAVL1). Serial statistical and 
functional enrichment clustering identified a cluster of 11 over-expressed ARE-mRNAs (CDC6, 
KIF11, PRC1, NEK2, NCAPG, CENPA, NUF2, KIF18A, CENPE, PBK, TOP2A) that negatively 
correlated with TTP/HuR mRNA ratios and involved in the mitotic cell cycle. This cluster was 
upregulated in a number of solid cancers. Experimentally, we demonstrated that the ARE-
mRNA cluster is upregulated in a number of tumor breast cell lines when compared to non-
invasive and normal-like breast cancer cells. RNA-IP demonstrated the association of the ARE-
mRNAs with TTP and HuR.  Experimental modulation of TTP or HuR expression led to changes in 
the mitosis ARE-mRNAs. Post-transcriptional reporter assays confirmed the functionality of 
AREs. Moreover, TTP augmented mitotic cell cycle arrest as demonstrated by flow cytometry 
and histone H3 phosphorylation. We found that poor breast-cancer patient survival was 
significantly associated with low TTP/HuR mRNA ratios and correlated with high levels of the 
mitotic ARE-mRNA signature. These results significantly broaden the role of AREs and their 
binding proteins in cancer, and demonstrate that TTP induces an anti-mitotic pathway that is 
diminished in cancer. 
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INTRODUCTION 
 
AU-rich elements (AREs) act as key cis-acting factors in the post-transcriptional control of gene 
expression;  abnormalities involving this pathway can occur in several diseases, including cancer 
(1). The AREs constitute instability determinant sequences located in the mRNA 3′UTR, and are 
fundamental to the transient expression of genes that regulate critical cellular functions, such 
as cell proliferation, apoptosis, cytokine response, and cellular motility (2,3). A growing body of 
evidence has linked aberrantly elevated and prolonged expression of ARE-encoding mRNAs to 
cancer, including those participating in angiogenesis, chemotaxis, and invasion. Examples of 
such genes include epidermal growth factor, estrogen receptor (ER), cyclooxygenase-2, vascular 
endothelial growth factor (VEGF), matrix metalloproteinase (MMP) 1, the chemokine receptor 
CXCR4, urokinase-type plasminogen activator (uPA) and its receptor (4-9). The ARE-mRNAs are 
regulated by trans-acting RNA-binding proteins notably tristetraprolin (TTP/ZFP36) and human 
antigen R (HuR/ELAVL1). TTP and HuR have antagonistic activities with regard to ARE-mRNA 
regulation; TTP destabilizes the mRNA and represses protein translation, whereas HuR is an 
mRNA-stability and translation-promoting factor (10-12). 
 
The dysregulation of the expression and function of TTP and HuR has been of particular interest 
and significance as they affect several cancer processes including cellular growth (13,14). The 
expression of TTP and HuR is regulated at the levels of transcription, mRNA stability, and 
translation; and their activity can be regulated at the post-translational level by 
phosphorylation, cellular localization, and protein stability (10,13,15,16). The mRNAs of TTP and 
HuR contain AU-rich elements, and their proteins are capable of regulating their own 
expression in an ARE-mediated manner (17-20). Additionally, we identified a TTP-HuR axis in 
which TTP reduces HuR mRNA and translation (18,21). Furthermore, TTP mRNA levels can be 
reduced by the high cellular levels of the microRNA 29a in invasive breast cancer (22). The 
inhibition of miR-29a using a cell-permeable anti-miR-29a peptide-nucleic acid can normalize 
the TTP-HuR axis, which leads to a reduction in the levels of ARE-mRNAs in breast cancer cells 
(21).  
 
Here, we performed a systematic analysis of ARE-mRNA expression in invasive breast cancer 
and across different types of cancer. We found an ARE-mRNA cluster that is: enriched in a 
mitotic cell cycle, highly co-regulated by key RNA-binding proteins, and correlated with 
patients' clinical outcome. We experimentally validated the expression patterns, functional 
responses to TTP and HuR, and the physical association of these mRNAs with their cognate 
proteins in cancer cells. Focusing efforts on pathways that significantly impact cancer 
processes, such as mitosis, may lead to new therapeutic approaches.  
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Materials and methods 
 
Cancer patient data  
The Oncomine web-based data mining platform (www.oncomine.com) was used to mine data 
from The Cancer Genome Atlas (TCGA) and METABRIC databases: http://cancergenome.nih.gov 
(23). Gene expression levels for 389 and 1556 invasive ductal breast cancer samples were 
downloaded for TCGA and METABRIC datasets, respectively, along with the 61 and 144 
corresponding matched normal samples. Cancer upregulated genes with 1.7-fold increase in 
expression and Q < 0.0001 were retrieved. Intersecting 2396 upregulated genes with 3658 
genes from the ARE database (ARED) (http://brp.kfshrc.edu.sa/ARED/) allowed the 
identification of the over-expressed AU-rich element-containing genes. Log2 median-centered 
intensity ratios were used. Other cancer datasets were used and extracted through Oncomine 
and Nextbio portals (Supplemental Table 1). 
 
Regression and volcano modeling for correlation studies 
See supplemental methods. 
 
Clustering and functional annotation 
Normal mixture was used for clustering and obtaining ARE-mRNAs with the most significant 
negative correlation with the TTP/HuR ratio. The input to the model was the 414 over-
expressed ARE-mRNA data from TCGA dataset, specifically: the correlation R-values of TTP 
mRNA with ARE-mRNAs, R-values of HuR mRNA with ARE-mRNAs, and the fold change of tumor 
to normal tissues (T/N). The Akaike Information Criterion (AIC) value was used as an indicator of 
goodness of fit (smallest AIC). The over-expressed ARE-mRNAs were analyzed using the AIC 
value and Johnson's transformation, which resulted in a best-fit normal mixture. Supervised 
hierarchical clustering and heat map visualization of gene expression data were performed 
using Gene-E (Broad Institute). Functional enrichment was performed using several web-based 
resources, including GEneSeT analysis http://bioinfo.vanderbilt.edu/ webgestalt/ analysis.php, 
Database for Annotation, Visualization and Integrated Discovery (DAVID), and STRING protein–
protein interaction resource http://string-db.org/.   
 
Cell culture and proliferation 
Cell lines were obtained from ATCC (2014 and 2015 batches). The normal-like mammary cell 
lines MCF10A and MCF12A were cultured in DMEM: F12 medium (Thermofisher) fortified with 
HuMEC supplement. The tumor breast lines MDA-MB-231, MCF-7, and HEK293 cells were 
grown in DMEM. The tumor breast cell lines BT-474 and SKBR were cultured in DMEM: F12 and 
McCoy’s; respectively. All media were supplemented with 10% FBS and antibiotics. Tet-On 
Advanced HEK293 cells were obtained from ClonTech (2013) and were cultured in DMEM 
supplemented with 10% Tet-System Approved FBS (ClonTech), 100 ug/mL G418 (Sigma), and 
antibiotics. Stocks were made at the original date of obtaining the cells, and were  usually 
passaged for no more than four months. Cellular proliferation was assessed by using real-time 
label-free electric impedance system (ACEA, San Diego) as previously described (24).  
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ARE reporter constructs and transfection 
The RPS30 promoter-linked reporter expression vectors (25) containing the AREs 
(Supplementary Table 4), were constructed by ligating two annealed synthetic complementary 
oligonucleotides with BamHI and XbaI overhangs. The annealed DNA were cloned in the 3′UTR 
the RPS30-SGFP vector. The use of RPS30 promoter along with SGFP, an EGFP generated from 
UW-reduced coding region (26) allows selective post-transcriptional effects. Co-transfection 
with RPS23-linked RFP was performed in HEK293 using lipofectamine 2000 (Invitorgen). The 
induced expression of HA-tagged TTP and myc-tagged HuR were used as previously outlined 
(4,5,21).  
 
Tet-on TTP induction and effect on ARE-SGFP reporters 
Tet-On TTP expressing constructs were prepared by PCR as previously described (27). The HA-
TTP construct was originally obtained from Dr. Perry Blackshear, NIH. The HEK-Tet-On advanced 
cells to study the TTP effect were seeded in six replicates in 96-well clear-bottom black plates 
and co-transfected overnight using lipofectamine 2000 with 50 ng of RPS30-SGFP-ARE 
constructs along with 10 ng of the Tet-On-TTP PCR product. Fluorescence was measured 24 hr 
after treating the cells with 0.2 μg/mL of doxycycline using the BD Pathway 435 imager (BD 
Biosciences) as reported previously (27). 
 
TTP and HuR over-expression 
Transient transfection of TTP in the TTP-deficient MDA-MB-231 cells was performed using 
lipofectinamine 2000.  For HuR overexpression experiments, MCF10A cells were seeded in 6-
well plates and transfected with 1 µg of pcDNA3.1-HuR plasmid or vector alone using 
Lipofectamine 2000. Total RNA and protein was extracted 24 hours after transfection for qPCR 
of the 11 identified mRNAs and immunoblotting. 
 
RNA Interference  
Two different small interfering RNA (siRNA) duplexes were synthesized by Metabion (Germany):  
HuR siRNA-1 (sense: 5′UGUGAAAGUGAUCCGCGAC3′ and antisense: 
5′GUCGCGGAUCACUUUCACA3′) and HuR siRNA-2 (sense: 5′GCCUGUUCAGCAGCAUUGG3′ and 
antisense 5′CCAAUGCUGCUGAACAGGC3′)  while the scrambled siRNA sequence is as follows 
(sense: 5′GCCAUGUAUACGCGGUUC3′ and antisense: 5′GAACCGCGUAUACAUGGCC3′).  MDA-
MB-231 or HEK293 cells were transfected with 50 nM of the siRNA for 48 hr,  RNA was 
extracted for RT-QPCR or fluorescence was quantitated, respectively. HuR silencing efficiency 
was verified by immunoblotting. 
 
Quantitative real-time PCR 
Total RNA was extracted (TRI reagent, Sigma) and reverse transcribed as described previously 
(5). QPCR was performed in multiplex using FAM-labeled Taqman primer and probe sets 
(Applied Biosystems, Foster City, CA, USA) as outlined in Supplemental Methods, and 
normalized to VIC-labeled human GAPDH as the endogenous control. Samples were amplified 
in triplicate in a CFX96 cycler (Bio-Rad), and quantification of relative expression was performed 
using the ∆∆Ct method.  
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Immunoprecipitation of RNP complexes 
HEK-293 cells (10 cc plates) were transfected with lipofectamine 2000 overnight with 2 µg 
pcDNA3.1 vectors expressing either HA-tagged-TTP or myc-tagged HuR along with either 100 ng 
of RPS30-SGFP or RPS30-SGFP-TNF-ARE as controls. TTP and HuR-associated RNA species were 
obtained using the detailed RNA-IP protocol outlined in Supplemental method.   
 
Western Blotting: 
Western blotting was performed as previously described (5).  Specific antibodies to TTP, HuR, 
and serine phosphorylated H3 histone were obtained from Santa Cruz.  Anti-HA and anti-β actin 
was obtained from Roche and Cell Signaling, respectively. 
 
Mitosis assessment: flow cytometry and histone phosphorylation 
MDA-MB-231 Tet-Off cells (28) were seeded with or without Tetracycline (1 μg/ml). After 24 hr 
Nocodazole was added to the cells to enrich for G2/M phase for 16 hr. Generally, we used 30 
μg/ml of the drug as higher concentrations (e.g., 100 μg/ml) led to over-arrested G2/M and 
toxicity. Cells were trypsinized, treated with DNase (2U/ul, Ambion), washed with PBS, fixed 
with 70% ethanol. Then, cells were washed with PBS, treated with RNase (100 μg/ml) and 
simultaneously stained with propidium iodide (25 μg/ml) for 30 min at 37°C for cell cycle 
analysis.  Proteins extracted from the cells immunoblotting and probed with rabbit anti-
phosphorylated Histone H3 (Ser 10, Santa Cruz). 
 
Survival analysis 
The Kaplan–Meier survival analyses were performed using the Kaplan–Meier plotter portal 
(http://kmplot.com/analysis/), a comprehensive dataset for survival analysis that covers cross-
normalized expression data of 54,675 genes in 4,142 breast cancer patients (29). The database 
was built from the gene expression and survival data extracted from the European Genome-
Phenome Archive (EGA) and the Gene Expression Omnibus (GEO) repositories. Overall survival, 
recurrence-free survival,, and distant metastasis free survival were determined using gene 
cluster stratification. In addition, survival analysis in the METABRIC and TCGA RNA-seq 
databases was performed separately. Associations between gene expression and patient 
survival were assessed by the Kaplan–Meier method (log-rank test, Graphpad 6.0 (30). The 
percentile threshold algorithm (25) was used to determine the optimal cut-off of the ARE-
cluster members. The JETSET best probe set was selected in case multiple probe sets measured 
the same gene to ensure the optimal probe set for each gene. Hazard ratios and p-values were 
determined by Cox proportional hazards regression. 
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Results 
 
ARE-gene expression and TTP deficiency are over-represented in cancer 
We performed a comprehensive analysis of ARE-mRNA expression across several cancer types 
(Fig. 1A). We intersected the AU-rich element mRNA database (ARED) with over-expressed 
genes (tumor/normal: >1.7, Q< 0.0001; two-sample t-test) extracted from different large cancer 
datasets (Supplementary Table 1). We found that the cancer ARE-mRNAs were significantly 
over-represented (13–23%) when compared to the overall cancer-over-expressed mRNAs 
(~7.2%), which makes an enrichment of 2- to 3-fold, (p<0.0001; One sample one-sided tailed t-
test)  (Fig. 1B).  
The TTP mRNA is generally found deficient in different cancers, with a 3- to 6-fold reduction 
compared to normal tissues (Fig. 1C). It was most deficient in breast cancer; density plots 
clearly illustrate the dramatic differences in TTP levels in normal versus cancer tissues in two 
large datasets (Fig. 1D). Due to this particular reduction in TTP gene expression and the large 
size of data available, further systemic analyses of ARE-mRNA expression patterns and their 
relation to TTP and HuR levels were conducted initially in breast cancer. All over-expressed 
genes with at least 1.7-fold increase (p < 0.0001, two-sample t-test) were retrieved from TCGA-
IDBC data and crossed with the ARED (2). A total of 414 over-expressed ARE-mRNAs were 
derived (Supplemental Table 2). 
 
Correlation modeling of TTP/HuR axis and alternative polyadenylation of HuR 
We looked at the relationship between HuR and the expressed levels of the cancer ARE-mRNAs. 
HuR has three polyadenylation variants as previously reported by us and others (18-20). 
Therefore, we examined the probe sets (Affymetrix) in the TCGA breast cancer dataset, and 
found there were two different sets for HuR (ELAVL1) mRNA, one that targets the most 
abundant variant (2.7 kB) and another that targets the long 6 kb variant (Fig. 1E). The probe set 
that detects abundant HuR variants exhibits over-expression of HuR in breast cancer. In 
contrast, the probe set that specifically targets the distal (6 kb mRNA) 3′UTR appears to be 
under-expressed compared to normal tissues (Fig. 1F). In METABRIC dataset (23), there is only 
one probe (Illumina), which is directed to the distal 3′UTR and thus the 6 kb variant, and, 
indeed, gave under-expressed levels of HuR in tumor tissues compared to normal tissues (Fig. 
1F). This observation is also found with other types of cancer; particularly, brain and lung 
cancer (Supplementary Fig. 1). Thus, we focused on the probe set that targets the most 
abundant form of HuR transcript variants, which also is over-expressed in cancers.  
 
Next, we performed expression/correlation analysis by integrating both the levels of TTP and 
HuR mRNAs. The TTP/HuR mRNA ratios were computed since the balance of these RNA-binding 
proteins can influence the expression of certain ARE-mRNAs (21). We tested the correlation of 
the TTP/HuR mRNA ratio with the expression patterns of the 414 ARE-mRNAs using the fit 
model; the result was significant, R2 = 0.98 (p < 0.001; Pearson’s correlation with Fisher’s test of 
significance Fig. 1G).  Moreover, the volcano plot shows that a large proportion (47%) of ARE-
mRNAs have a negative correlation with TTP/HuR mRNA level ratio (198 ARE-mRNAs with R-
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values < −0.3 and p-values < 0.0001-(-Log10 > 4) compared to non-ARE mRNAs (only 2.8% of the 
1979 non-ARE-mRNAs, Fig. 1H).  Supplementary Table 3 shows the identities of the ARE genes, 
R-values and P-values that correlate with TTP, HuR, or TTP/HuR mRNAs. In general, TTP levels 
correlated negatively with ARE-mRNAs, while HuR positively correlated with the ARE-mRNAs 
when compared to non-ARE-mRNAs (Supplemental Fig. 2).  Overall, this data clearly shows that 
it is much more likely for over-expressed ARE-genes to negatively correlate with low TTP/HuR 
ratio than over-expressed non-ARE genes. 
 
Step-wise functional clustering analyses for cancer ARE-mRNAs  
To derive further correlation and functional clustering of the cancer ARE-mRNAs that depend 
on TTP/HuR mRNA ratio, the Normal Mixture model was used to find the most significant 
cluster of genes (Fig. 2A). Although we have used stringent criteria on the expense of 
sensitivity, several known TTP/HuR ARE-mRNAs such as uPA (PLAU), PLAUR, and MMP13 were 
found (Supplementary Table 2). Five clusters were generated, and the total squared correlation 
among the three parameters was highest (R=0.81) in cluster five, which contained a 23-ARE-
mRNA cluster (Fig. 2B). The expression levels of this cluster in the breast tumors and the normal 
tissues from the TCGA dataset are illustrated on a heat map demonstrating significant cancer 
upregulation for each cluster member (Fig. 2C).  
 
Directed acyclic graphs (DAG) enriched in Gene Ontology (GO) categories, each as a node in a 
network, were built through GEneSeT analysis (Fig. 2D). The mitotic (M) cell cycle was the most 
significant node and comprises 11 genes, which are CDC6, CENPA, CENPE, KIF11, KIF18A, 
NCAPG, NEK2, NUF2, PBK, PRC1, and TOP2A. An enrichment (7-fold) of this category was 
observed when this ARE-mRNA cluster is compared to all TCGA over-expressed genes (p < 
0.0001; Chi-square test). The protein interaction module, which is based on DAGs, reveals that 
the highest enrichment (p=6.70e–11) are in DNA replication-independent nucleosome assembly 
and microtubule motor activity; both are within the M-phase of cell cycle category (Fig. 2E). The 
use of STRING analysis confirmed the significant protein interactions among the gene nodes 
(Fig. 2E, large inset).  
 
Bioinformatics and gene expression of M cell cycle ARE-mRNAs  
The weighted means of the different ARE-clusters between tumor and normal tissue ratios 
were calculated (Fig. 3A). As a whole, the 414 over-expressed ARE-mRNAs were slightly, 
although statistically significantly (p < 0.001) higher than non-ARE over-expressed control set 
genes (n = 1979). However, the TTP/HuR-correlative 23-ARE-mRNA cluster weighted mean has 
significantly higher expression ratios (∽5-fold) compared to both the total over-expressed ARE- 
and non-ARE-mRNAs (Fig. 3A). The 11 M cell cycle ARE-mRNAs were significantly higher than 
other gene sets (6-fold of the weighted mean, p < 0.001, two-sample t-test; Fig. 3A). The data of 
individual expression levels and correlations of the 11 ARE-mRNA cluster demonstrate 
significant upregulation and negative correlation with the TTP/HuR mRNA ratio (Supplementary 
Fig. 3 & 4).  
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Further, we looked at the expression patterns of the ARE-mRNA cluster across 10 different 
types of cancers. The expression of 11 ARE-mRNAs was upregulated in a number of different 
cancers as shown in the heat map (Fig. 3B). The up-regulation of the mean expression (non-
weighted mean) of the M ARE-mRNA cluster is also obvious across the different cancers (Fig. 
3C). 
 
By RT-QPCR, we evaluated the expression levels of the M cell cycle ARE-mRNAs in a number of 
cell lines (Fig. 3D and E). Overall, the mRNA levels were higher in the triple-negative MDA-MB-
231 cells compared to moderately-tumorigenic ER-positive, MCF-7, and normal-like breast 
cancer cells MCF10A and MCF-12A, respectively (Fig. 3D). Using different panel of cells, HER-
positive/ER-negative status, we also found that all the ARE-mRNAs (except CENPA, which had 
very low levels) were highly expressed when compared to the normal-like cells (Fig. 3E).  In 
particular, the mRNA levels in HER-positive ER-/PR-negative SKBR3 was the highest when 
compared to other lines in the panel (Fig. 3E). In general, these results are in agreement with 
the observations made in the patient tissues' datasets in which these ARE-mRNAs are over-
expressed in invasive ductal breast cancer. 
 
Anti-mitotic effect of TTP 
Based on the computational approach, TTP could be functionally related to M-phase of the cell 
cycle. Thus, we have utilized TetO/TTP-regulated MDA-MB-231 cell line (28); with removal of 
tetracycline, the cells express TTP and exhibit reduced proliferation (Fig. 4A). When cells were 
treated with nocodazole, TTP behaves as an anti-mitotic protein and blocked cell cycle at G2/M 
phase as determined by flow cytometry (Fig. 4B). Furthermore, we showed that histone H3 
phosphorylation, a marker of mitotic arrest, is higher when TTP is expressed in the nocodazole-
treated cells (Fig. 4C). A confirmatory experiment was performed using transient expression of 
TTP in MDA-MB-231 cells (Fig. 4D).  
 
Reporter assessment of ARE activity and response to TTP induction 
The putative AREs of the 11-gene cluster and their context sequences were cloned in the 3’ UTR 
of fluorescent reporter assays (Fig. 5A). A heat map was constructed to reflect the strength of 
the TTP target sequence UUAUUUAUU/UAUUUAU (Fig. 5A), which shows that NEK2, CENPE, 
and NCAPG AREs have Class-II- like ARE while the rest are largely Class-I AREs; that is, AUUUA in 
a U-rich context (Fig. 5A and supplementary Table 4).  We used HEK293 cell line, which is 
suitable for weak fluorescence-based reporter assays. Seven of the AREs caused a reduction in 
the reporter activity demonstrating functional and active AREs (Fig. 5B). Statistically significant 
reductions ranged from 25% (CDC6) to 50% (CENPE, NEK2), which share the strongest TTP 
target sequence score (Fig. 5B). The IL-8 ARE caused 52% reduction in reporter expression. The 
mRNAs for CENPA, PRC1, and TOP2A, although not statistically significant, they demonstrated a 
modest 25% reduction in reporter fluorescence compared to the non-ARE control (Fig. 5B). 
Also, most responded to TTP induction or HuR knockdown to varying degrees of reduction (Fig. 
5C and D).  
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Physical association and response of the M ARE-mRNAs to TTP and HuR  
We investigated the possible physical association of TTP with the 11 M cell cycle ARE-mRNAs by 
over-expressing an HA-tagged TTP (HA-TTP) construct in HEK-293 cells. The 
immunoprecipitation of TTP was confirmed by western blotting (Fig. 6A). The RNA-IP clearly 
shows that the SGFP-TNF-ARE reporter mRNA is highly enriched on the HA-coupled beads 
compared to the myc-coupled beads (> 30-fold enrichment). The ARE-containing known TTP 
target, IL-8 mRNA, is highly enriched in the TTP-HA IP sample (∽23-fold) but not mRNAs of non-
ARE housekeeping genes (Fig. 6A). Next, the association of 10 of the ARE-mRNAs was 
investigated (CENPA expression was below detection levels) by RT-QPCR and all were found to 
be enriched with TTP (Fig. 6A). The enrichment degree varied between 6-fold (CENPE) and 20-
fold (PBK). As independent experiments, TTP-associated ARE-mRNAs were assessed in MDA-
MB-231 using an alternative RNA-IP protocol (21) and further confirmed that TTP bound the 
ARE-mRNAs except CENPA which its levels were too low (Fig. 6B). Exogenous expression of TTP 
led to reduction of the majority of the 11 ARE-mRNAs (except NCAPG) (Fig. 6C). 
 
The binding of HuR to the 11 ARE-mRNAs were assessed in a similar manner using transfected 
anti-myc tagged HuR. (Fig. 6D). The immunoblot shows the specificity of the antibody (Fig. 6D 
inset). Although the bindings to the different 11 ARE-mRNAs were modest compared to TTP, it 
is within the same degree as with the HuR mRNA target of IL-8 and is statistically significant 
(Fig. 6D). NEK2 mRNA has the strongest binding (3-fold) while TOP2A and PRC1 mRNAs were 
the weakest. These results demonstrate the physical association of the RNA-binding proteins 
TTP and HuR with the ARE-mRNA mitotic cluster.  
 
We have also assessed the outcome of HuR knockdown in MDA-MB-231 (Fig. 6E), which has 
high levels of HuR (21), on the expression of the 11 ARE-mRNAs, and found that siRNA-
mediated silencing caused significant reduction in the mRNA levels (Fig. 6F). Using the non-
transformed MCF10A which generally has low levels of HuR (21), we found that over-expressed 
HuR was able to augment the M cell cycle ARE-mRNA levels (Fig. 6G). 
 
Association of M cell cycle ARE cluster and cancer patients' survival 
Patient classification to low and high mean expression of the M cell cycle ARE-mRNA cluster 
(Fig. 7A) inversely corresponds as expected with the TTP/HuR mRNA ratio (Fig. 7B). Poor 
relapse-free survival (RFS, n = 4073 patient data) was observed with the high M cluster cohort 
(p <10e-10, log-Rank test; and hazard ratio (HR) = 2.4) (Fig. 7C). Similarly, poor outcome was 
observed in distant metastasis-free survival (DMFS, HR = 2.4) (Fig. 7D) and in overall survival 
(OS, HR = 2.13, Supplemental Fig. 5A). We repeated the survival analysis in the non-Affymetrix 
METABRIC database (n = 1959) and the RNA-seq data (n=781) and data demonstrate poor 
survival with higher mean expression of the mitotic ARE-mRNA cluster (Supplemental Figure 5 B 
and C).  
  
Testing direct correlation of patients’ survival with TTP/HuR mRNA ratio stratification, we found 
that the cohort with the low TTP/HuR mRNA ratio had poor survival outcome (Fig. 7E).  Poor 
survival (higher HR) in relation to the low TTP/HuR mRNA ratio, is more prominent with ER-
positive cases and negative lymph node involvement (Fig. 7F). The 11 M ARE-mRNA cluster was 
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also more significantly associated with poor survival in case of ER-positive and HER-negative 
tissues (Fig. 7G). It appears that the TTP/HuR mRNA ratio and the ARE-mRNA cluster is more 
associated with survival in patients with lower grade tumors (Fig. 7F). Overall, high expression 
of the mitotic ARE cluster and their association with a low TTP/HuR mRNA ratio is indicative of 
poor survival in breast cancer patients.  
 
 
12 
 
Discussion 
 
Alterations in ARE-mediated pathways are prominent post-transcriptional events that are 
increasingly studied in cancer. Only a small set of ARE-mRNAs have been previously shown to 
be over-expressed in cancer and regulated by the key RNA-binding proteins, TTP and HuR (For 
an updated list, see our review (1). In this study, we expanded cancer ARE-mRNAs to nearly 200 
ARE-mRNAs that correlate negatively with TTP and positively with HuR expression. Further 
statistical and functional enrichment, and experimental validation led to the identification of 11 
ARE-mRNAs, which code for proteins involved in the mitotic (M)-phase of the cell cycle. The 11 
mitosis members perform critical roles in M phase of the cell cycle (31). Thus, TTP may promote 
G2/M arrest by the fine-tuning the temporal expression of these ARE-mRNAs.  
 
The systemic study conducted here shows that ARE-mRNA expression is over-represented in 
multiple cancer types adding to the significance of the ARE-mediated post-transcriptional 
control in cancer. In these same types of tumors, TTP deficiency is observed and is linked to 
nearly half (198 genes) of the over-expressed ARE-mRNAs in breast cancer as assessed here. A 
deficiency of TTP can lead to the increased growth of cancer cells, because TTP targets those 
mRNAs involved in cellular proliferation, such as the previously identified cyclin D1 myc, E2F1 
and IL-6 (32,33) and also the M cell cycle ARE-mRNAs newly identified here. Modulation of TTP 
in breast and other cancer cells by ectopic expression impacts cellular growth and attenuates 
tumor xenografts in mice (28,34,35) which in agreement with the patients’ data here.  
 
 While TTP is deficient in cancer, HuR, which stabilizes ARE-mRNAs is often over-expressed in 
tumors or its cytoplasmic localization is increased (36-41). HuR is more of a general RNA-
stability promoting protein with preference towards AU/U-rich sequences (42). Here, we also 
expanded (more than 100 mRNAs) HuR-correlated ARE-mRNAs that are linked to cancer. HuR 
mRNA has three alternative polyadenylation forms of 1.5 kb, 6 kb long variant, and the most 
abundant form is 2.7 kb transcript (18). HuR autoregulates its own mRNA at the post-
transcriptional level (18) (19,20). The lower expression of the long variant in contrast to the 
over-expression of the shorter (and abundant) mRNA variant in cancer can be explained by 
defects in the polyadenylation process, which can favor the abundant variant. This may be 
consistent with the cell line work of two groups (19,20). In general, HuR has been shown to 
block polyadenylation and cleavage at polyadenylation sites that are flanked by U-rich 
sequences (43). Thus, our data notably extend these laboratory HuR transcript expression 
patterns to patients’ tissues. Furthermore, this brings attention to the fact that different probe 
sets directed towards different regions of the same transcript, including polyadenylation 
variants, can have an impact on the interpretation of microarray expression results, including 
the expression direction. 
 
We focused analysis on TTP/HuR mRNA aberrations and correlation with the cancer genes 
because a TTP-HuR axis exists in cells: TTP competes for HuR binding and can reduce HuR mRNA 
expression (18,21). Further mechanistic details showed that phosphorylation of TTP by MK2 
alters that balance towards ARE-mRNA stabilization and translation (11,44), and more recent 
work confirmed that TTP targets the HuR mRNA (45). Another evidence for the TTP-HuR axis is 
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the ability of the miR-29a which targets TTP 3′UTR in breast cancer cells (22) to alter the normal 
TTP-HuR balance, while miR-29a inhibitor restores the reversed balance. This leads to reduction 
of the cellular levels of ARE-mRNAs and their proteins; for example, uPA and CXCR4 in cancer 
cells (5,21).  
 
The M cell cycle ARE-mRNAs either as individuals or as a group (weighted mean) were not only 
over-expressed in the invasive breast tumor tissues but were over-expressed across a number 
of solid tumors, including liver, lung, bladder, brain, stomach, and kidney. This implies that 
there is a wide-spread effect of dysregulated ARE-mediated post-transcriptional processes in 
controlling M cell cycle in cancer. Other findings do not rule out other regulatory mechanisms 
that are abnormal in cancer such as transcription, since these genes are tightly co-expressed. 
 
Another potential and important ramification of TTP deficiency and HuR over-expression is the 
impact on angiogenesis, tumor invasion, and metastasis as it targets ARE-mRNAs that mediate 
such processes, including IL-8, VEGF, IL-6, uPA, uPAR, CXCR4, and MMP13 (4-6,46,47). TTP has 
been shown to significantly reduce tumor cell migration and invasion while HuR increases these 
activities (4,5,21,48,49). The combined impact on mitosis and tumor invasion due to lack of TTP 
in breast cancer cells and patients may confirm the putative tumor suppressor role of TTP, 
including its anti-invasive role. The strikingly low number of patient samples with normal TTP 
and TTP/HuR levels allows the suggestion that the repression of TTP might be an "essential 
factor" at least in invasive breast cancer. Those who have levels that are not dramatically 
reduced had better prognostic outcomes. There was significant stratification of survival based 
on TTP/HuR mRNA ratios and the M-phase cell cycle ARE-mRNA clusters in breast cancer 
patients, particularly with low-grade, lymph-node negative and ER-positive status. Thus, 
targeting the TTP-HuR axis, and thereby reducing the M cell cycle and invasiveness of the 
cancer cells, either by increasing TTP or directly by reducing HuR, may have beneficial effects in 
patients. Our results can give more insights to the role of the post-transcriptional network in 
cancer maintenance with new therapeutic approaches in mind. 
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Figure legends  
 
Figure 1: Systemic analysis of ARE-mRNAs and TTP expression in cancer. A) Schematic 
representation illustrating the approach used for deriving a list of over-expressed ARE-mRNAs 
in cancer types. Gene expression levels were mined from 20 datasets representing 10 cancer 
types (Datasets, Supplemental Table 1). The threshold for over-expression was set as 1.7-fold of 
tumor to normal (T/N) and Q < 0.0001. Over-expressed ARE-mRNAs for each dataset were 
determined by intersecting total over-expressed genes with the ARED database. B) Percentage 
of ARE-mRNAs that are over-expressed in the different cancer types in proportion to the total 
expressed mRNA in each cancer. C) T/N level Fold of TTP mRNAs were obtained from each 
cancer dataset. D) Density frequency plot of TTP mRNA levels in normal (green) and tumor 
tissues (brown) using the indicated dataset. E) Schematic representation of the three different 
HuR polyadenylation mRNA variants. The relative probe target locations (arrows) are shown 
(Affymetrix probe starts with A_ and Illumina with ILMN). pA: poly A signal. Boxes (between 
vertical lines) denote exons. F) Tumor/Normal levels of HuR mRNA by probe ID. G) Scatter plot 
using fit model for the correlation between TTP/HuR mRNA ratios and the cancer 414 ARE-
mRNAs. H) Volcano plots for TTP/HuR mRNA ratio comparative correlation with ARE- and non-
ARE cancer mRNAs by significance (−log10 p-value) as described in Materials and Methods. Pie 
plots depict the percentages of ARE-mRNAs (upper) or non-ARE-mRNAs (lower) that according 
to the correlation. Vertical dotted lines denote: negative correlation (R<-0.3, p<0.001), or 
positive correlation (R>0.3) with TTP expression levels. Pearson’s correlation with Fisher’s exact 
test for significance (p-value) was used. 
 
Figure 2: Clustering analysis of cancer ARE-mRNAs with TTP and HuR expression. A) Normal 
mixture clustering analysis based on the correlation (R)  of the T/N expression ratios (Fold) of 
the 414 over-expressed breast cancer ARE-mRNAs with that of TTP and HuR. B) Heat map 
visualizing the most significant cluster (Cluster Five) containing 23 ARE-mRNA showing fold (T/N 
mRNA ratio) and ARE-mRNA correlations (R-values) with HuR and TTP mRNA levels. Legend 
shows the scale for each parameter. C) Heat map visualizing the over-expression of the 
resultant 23 ARE-mRNA cluster in the invasive ductal breast cancer. D) Functional annotation of 
the 23 genes using GEneSeT analysis: enriched GO categories are in red (multiple tests adjusted 
P-value) while those in black are their non-enriched parents. Pie charts showed the most 
enriched GO categories using DAVID. E) Modules of enriched protein interactions (in red lines) 
on directed acyclic graphs (DAGs). Green nodes indicate the mitotic proteins. The large inset 
shows the STRING analysis of known and predicted protein–protein interactions among the 11 
ARE-mRNA gene products. The nodes indicate proteins, and the edges indicate interaction 
between these genes.  
 
Figure 3. Expression of the ARE-mRNA mitotic cluster in cancer. A) The weighted means of T/N 
ratio for the indicated ARE-mRNA clusters that correlated with TTP/HuR. Level 2 raw data was 
obtained from TCGA invasive ductal breast cancer dataset. B) A heat map was generated to 
visualize the over-expression of the mitotic cell cycle ARE-mRNAs in 10 different cancer types. 
C) The mean expression (non-weighted mean) of the combined fold increase of the 11 M ARE-
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mRNAs was derived from the Nextbio portal using several cancer types. No SEM data are given 
from the Nextbio output, but P-values are reported (numbers are shown). D) The normal MCF-
10A and MCF-12A, as well as the breast tumor cell lines triple-negative MDA-MB-231 and ER-
positive/Her-negative, MCF-7, were grown in six-well culture plates. Total RNA was extracted, 
and the mRNAs were quantitated by RT-QPCR using TaqMan specific primers and were 
normalized to the housekeeping gene, RPLPO. E)  The mRNA levels of the 11 ARE-mRNA cluster 
in MCF10A and the HER2 positive cell lines BT474 and SK-BR3 using RT-QPCR as above.  Data 
are from one experiment representative of at least two independent experiments. In both D and 
E, statistical significance was assessed by one-way ANOVA, with underlined values of *p< 0.05, 
**P<0.01, *** P<0.0001. Post-Hoc tests, Dunnett’test for comparison with MCF10A or Tukey’s  
(with each normal-tumor pair) were used, *p < 0.01, **p < 0.0001.  
 
Figure 4. The anti-mitotic effect of TTP 
(A) Continuous monitoring of cell proliferation of MDA-MB-231 Tet-off cells in the presence or 
absence of tetracycline (1 μg/ml). (B) After 24 hr of tetracycline treatment, nocodazole (30 
μg/ml) was added to the cells for 16 hr to enrich for G2/M-positive cells. Data are 
representative of three flow cytometry experiments. (C) MDA-MB-231 Tet-Off cells were 
treated with tetracycline and nocodazole as indicated in B and protein was extracted for 
immunoblotting with anti-p-Histone H3 or β-actin. The experiment is representative of two 
independent experiments. (D) Transient expression of TTP and histone H3 phosphorylation. 
MDA cells were transfected with TTP or vector, followed by nocadzole treatment (16 hr). 
Western blotting showed anti-phosphorylated H3 and actin control. 
 
 
Figure 5. Reporter assessment of ARE activity and response to TTP induction. A) A scheme 
representing the AREs of the M cycle ARE-mRNAs along with the cluster membership according 
to the ARED. The color score represents strength of TTP sequence in which 1 = perfect match 
with UUAUUUAUU. B) HEK293 cells were transfected with the RPS30-SGFP-ARE reporters along 
with control vector (non-ARE) and positive control (IL-8 ARE) as described in Materials and 
Methods.   Fluorescence was measured after 24 hr and presented as % Mean of control + SEM. 
C) TTP effect on ARE-reporter expression. A Tet-O inducible TTP expression cassette was co-
transfected with each of the reporter constructs in HEK-Tet-ON cells. TTP was induced by 0.2 
μg/mL doxycycline treatment, and the effect of TTP was assessed 24 hr later by quantifying the 
level of the reporter fluorescence. D) HuR knockdown and ARE reporter activity. HEK293 cells 
were treated with 50 nM control siRNA or HuR siRNA for 24hr and transfected as above. 
Fluorescence was quantified after another 24 hr. *p<0.05, **p < 0.005, ***p < 0.001, ****p < 
0.0001 using Student’s t-test.   
 
Figure 6. RNA/protein immunoprecipitation and modulation of TTP and HuR  A) RNA/Protein 
co-immunoprecipitation of TTP with the putative M ARE-mRNA cluster. HA-TTP HEK293 
transfected cells were lysed and TTP protein was immunoprecipitated with anti-HA coupled 
beads. The negative control (NC) IP was performed with anti-myc. TTP-IP was confirmed by 
western blotting (insets). TTP-associated mRNA levels were assessed by RT-QPCR and 
normalized to RPLPO as background control. The non-ARE mRNAs of GAPDH, GUS, and RPLP1 
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were used as internal negative controls while IL-8 ARE-mRNA as control. B) MDA-MB-231 cells 
were transfected with TTP expression plasmid for 24 hr.  Cells were lysed and TTP protein was 
immunoprecipitated using anti-TTP antibody or normal IgG control antibody. Associated mRNA 
was quantified by RT-QPCR using gene-specific probes normalized to GAPDH. C) TTP-mediated 
downregulation of M ARE-mRNA in MDA-MB-231 cells. Cells were transfected with 10 ng TTP-
pcDNA3.1 plasmid and 500 ng DNA with pcDNA3.1 empty vector or transfected with 500 ng 
empty vector alone.  Total RNA was extracted after 24 hr and RT-QPCR of 11-genes plus positive 
and negative controls were performed as in (A).  D) The binding of myc-HuR to the 11 M ARE-
mRNAs was assessed in a similar manner to A. The myc-HuR IP was performed on anti-myc 
coupled beads, and the negative control IP with anti-HA coupled beads. The same positive and 
negative control mRNAs were used as in A). (E, F) HuR silencing and the  M ARE-mRNA  cluster 
in MDA-MB-231.  The cells (0.5 x 106) were transfected with 50 nM HuR siRNA-1, HuR siRNA-2 
or scrambled siRNA control for 48 hr. HuR silencing efficiency was determined by Western 
blotting.  The mRNA levels were determined by RT-QPCR using HuR siRNA-2 samples. Data are 
from one representative experiment of at least two independent experiments. G) Effect of HuR 
over-expression on the M ARE-mRNA levels in MCF10A.  Cells (0.5 X 106 cells) were transfected 
with 1 ug of pcDNA3.1-HuR plasmid or vector alone and RNA was extracted after 24 hr for RT-
QPCR. The results are from one experiment representative of two independent experiments. 
For all data above: * P <0.05, ** P <0.005, *** P < 0.0001 (Student’ t-test) shown for each ARE 
mRNA in comparison to the control.   
 
Figure 7. Clinical outcome of the M cell cycle TTP/HuR correlated ARE-mRNA expression  
A) A heatmap for M ARE-mRNA expression cohorts. Data in Kaplan–Meier portal was used to 
classify the data into low and high expressing M ARE-mRNA cohorts in relation to the clinical 
outcome. The dotted line represents the best cutoff. B) TTP/HuR mRNA ratio levels of the two 
expression cohorts. The best cut-off was based on the expression levels of the ARE-mRNA 
cluster shown in (A). C) Kaplan–Meier survival curves generated in accordance with expression 
classifiers in (A) using RFS: relapse-free survival (C) or DFMS, distant metastasis free survival (D). 
E) Kaplan–Meier survival curve using TTP/HuR mRNA classifiers. Grade, lymph-node 
involvement, and receptor status in patients with TTP/HuR mRNA classification (F) and M cell 
cycle ARE-mRNA cluster (G). P values (numbers) and hazard ratio (HR) are indicated. Q square 
test was used to evaluate the statistical significance between each group member, *P<0.01, 
**<0.001, ***p<0.0001.  







